Your browser doesn't support javascript.
loading
Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆.
Gaspar, N; Campbell-Hewson, Q; Gallego Melcon, S; Locatelli, F; Venkatramani, R; Hecker-Nolting, S; Gambart, M; Bautista, F; Thebaud, E; Aerts, I; Morland, B; Rossig, C; Canete Nieto, A; Longhi, A; Lervat, C; Entz-Werle, N; Strauss, S J; Marec-Berard, P; Okpara, C E; He, C; Dutta, L; Casanova, M.
Afiliação
  • Gaspar N; Department of Childhood and Adolescent Oncology, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: nathalie.gaspar@gustaveroussy.fr.
  • Campbell-Hewson Q; The Great North Children's Hospital, Royal Victoria Infirmary, Newcastle Upon Tyne, UK.
  • Gallego Melcon S; Pediatric Oncology and Hematology Service, University Hospital Vall d'Hebron, Barcelona, Spain.
  • Locatelli F; Department of Pediatric Hematology and Oncology, Ospedale Pediatrico Bambino Gesù, University of Rome, Rome, Italy.
  • Venkatramani R; Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, USA.
  • Hecker-Nolting S; Department of Pediatric Oncology, Hematology, Immunology, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany.
  • Gambart M; Pediatric Hemato-Oncology Unit, CHU Toulouse - Hôpital des Enfants, URCP, Toulouse, France.
  • Bautista F; Paediatric Haematology-Oncology Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
  • Thebaud E; Pediatric Oncology-Hematology and Immunology Department, CHU Nantes - Hôpital Mère-Enfant, Nantes, France.
  • Aerts I; SIREDO Oncology Center, Institut Curie, PSL Research University, Paris, France.
  • Morland B; Department of Paediatric Hematology/Oncology, Birmingham Children's Hospital, Birmingham, UK.
  • Rossig C; Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany.
  • Canete Nieto A; Children's Oncology Unit, Pediatric Service, Hospital Universitario y Politecnico La Fe, Valencia, Spain.
  • Longhi A; Chemotherapy Service, Istituto Ortopedico Rizzoli IRCCS, Bologna, Italy.
  • Lervat C; Pediatric and AYA Oncology Unit, Centre Oscar Lambret Lille, Lille, France.
  • Entz-Werle N; Pediatric Onco-Hematology Unit, Chu Strasbourg-Hôpital Hautepierre, Strasbourg, France.
  • Strauss SJ; Clinical Research Facility, University College London Hospitals NHS Trust, London, UK.
  • Marec-Berard P; Institute of Pediatric Hematology and Oncology, Centre Léon Bérard, Lyon, France.
  • Okpara CE; Clinical Research, Oncology Business Group, Eisai Ltd., Hatfield, UK.
  • He C; Biostatistics, Oncology Business Group, Eisai Inc., Woodcliff Lake, USA.
  • Dutta L; Clinical Research, Oncology Business Group, Eisai Inc., Woodcliff Lake, USA.
  • Casanova M; Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
ESMO Open ; 6(5): 100250, 2021 10.
Article em En | MEDLINE | ID: mdl-34562750
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Osteossarcoma / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Child / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Osteossarcoma / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Child / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article